---
title: "Tirabrutinib: Primary central nervous system lymphoma"
description: "Formulary evidence on Tirabrutinib in Primary central nervous system lymphoma. Clinical evidence covers PROSPECT, ONO-4059-02, IGNITE, ReSTART (JCOG2314), Japanese post-marketing surveillance, ROSETTA, and 15 further headings. 234 evidence topics quoted from 67 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Tirabrutinib: Primary central nervous system lymphoma

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Tirabrutinib

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Primary central nervous system lymphoma

<a id="topic-1.1.1-1"></a>

##### Summary

In U.S. registry data, PCNSL incidence increased from 0.1 to 0.5 per 100,000 between 1975 and 2017. Presentations include headaches, seizures, limb weakness, confusion, and visual or hearing disturbances. A Taiwan study reported mean direct healthcare costs exceeding 1 million TWD, approximately 35,000 USD, concentrated in the first year after diagnosis.

Source: [Lv et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8793121/); [National Cancer Institute PDQ patient version](https://www.cancer.gov/types/lymphoma/patient/primary-cns-lymphoma-treatment-pdq); [Hsiao et al. (2026a)](https://onlinelibrary.wiley.com/doi/10.1002/cam4.71707)

<a id="heading-1.1.2"></a>

#### 1.1.2 Tirabrutinib Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary

PROSPECT enrolled 48 participants with relapsed or refractory PCNSL. The reported overall response rate was 66.7%, the complete or unconfirmed complete response rate was 43.8%, median response duration was 9.3 months, and median progression-free survival was 6.0 months. Grade 3 or higher treatment-emergent adverse events occurred in 56.3%. Two participants died from treatment-emergent adverse events considered unrelated to study treatment.

Source: [Nayak et al. (2025a)](https://doi.org/10.1002/hon.70093_88); [ONO Pharma and Deciphera Pharmaceuticals (2025)](https://www.deciphera.com/news/ono-pharma-presents-positive-results-pivotal-trial-us-patients-relapsed-or-refractory-pcnsl-0)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Tirabrutinib

<a id="topic-1.1.3-1"></a>

##### Summary

The report contains a Japanese receipt-score-based tirabrutinib treatment cost of 0.91 million JPY per month. This is not a U.S. average sales price, wholesale acquisition cost, or population-level budget impact estimate. No tirabrutinib-specific budget impact model was identified.

Source: [Motomura et al. (2024)](https://academic.oup.com/jjco/article/54/10/1123/7747842)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

Tirabrutinib has Japanese approval and is identified in the EHA-ESMO guideline as an option for relapsed or refractory PCNSL. The U.S. application was accepted for review under the accelerated approval pathway, with a stated PDUFA date of December 18, 2026; this is not an approval. Japanese safety precautions specify permanent discontinuation for Stevens-Johnson syndrome or toxic epidermal necrolysis. The retained sources give different Taiwan approval dates: the company states February 2022, whereas the regulator's assessment report records October 29, 2021.

Source: [ONO Pharma USA (2023)](https://us.ono-pharma.com/news/tirabrutinib-receives-orphan-drug-designation); [Ferreri et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/hem3.89); [Deciphera Pharmaceuticals (2026)](https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-us-food-and-drug-administration-acceptance-filing-new-drug); [PMDA revision of precautions (2024)](https://www.pmda.go.jp/files/000269547.pdf); [Taiwan Food and Drug Administration assessment report](https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=40103&mid=189&t=s)

## Related pages
- [Tirabrutinib in Primary central nervous system lymphoma: Terms and abbreviations](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/terms-and-abbreviations.md)
- [Tirabrutinib: Primary central nervous system lymphoma](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/executive-summary) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/executive-summary.md)
- [Tirabrutinib in Primary central nervous system lymphoma: Product information and disease description](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/product-information-and-disease-description.md)
- [Tirabrutinib in Primary central nervous system lymphoma: Clinical evidence](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/clinical-evidence.md)
- [Tirabrutinib in Primary central nervous system lymphoma: Economic information and modeling report](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/economics) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/economics.md)
- [Tirabrutinib in Primary central nervous system lymphoma: References](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/references) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/references.md)
- [Tirabrutinib in Primary central nervous system lymphoma: prevalence by geography](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/prevalence) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/prevalence.md)
- [Tirabrutinib in Primary central nervous system lymphoma: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/cost-effectiveness-analyses.md)
